(RxWiki News) Lisinopril, which has been on the market for decades as an oral tablet often used to treat high blood pressure, recently gained FDA approval as an oral solution.
Silvergate Pharmaceuticals manufactures this new liquid formulation and has named it Qbrelis.
Qbrelis, the first and only lisinopril oral solution approved by the US Food and Drug Administration (FDA), is approved for the treatment of hypertension in patients ages 6 and older, for the treatment of heart failure (in combination with other medications) and for the treatment of acute heart attack in adults.
Because it is an oral solution and not a tablet, Qbrelis allows weight-based dosing for children who have previously had to rely on an adjusted adult dose. Adult patients who have trouble swallowing tablets may also benefit from having an oral solution option.
A boxed warning notes that Qbrelis is not for use in pregnant women because it can lead to fetal toxicity. Avoid the use of salt substitutes or potassium supplements while taking Qbrelis. Common side effects include headache, dizziness, cough and chest pain.
FDA evaluation criteria for Qbrelis was not available at the time of publication.
Talk to your doctor to see if Qbrelis is appropriate for you.
